Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Caux

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Immunity|October 13, 1998
A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartmentB de Saint-Vis, J Vincent, S Vandenabeele, et al.
Oncoimmunology|May 4, 2016
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assayE Verronèse, A Delgado, J Valladeau-Guilemond, et al.
ESMO Open|June 5, 2025
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trialL Collet, J-C Noël, X Catteau, et al.
The Journal of Biological Chemistry|June 20, 1998
Leukocystatin, a new Class II cystatin expressed selectively by hematopoietic cellsS Halfon, J Ford, J Foster, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasisB Homey, M C Dieu-Nosjean, A Wiesenborn, et al.
Oncogenesis|July 26, 2016
TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expressionP Parroche, G Roblot, F Le Calvez-Kelm, et al.
Oncoimmunology|September 14, 2020
Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcomaA Dufresne, T Lesluyes, C Ménétrier-Caux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockadeJ-P Foy, C Bertolus, M-C Michallet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsO Trédan, C Ménétrier-Caux, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsO Trédan, C Ménétrier-Caux, I Ray-Coquard, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Immunity|October 13, 1998
A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartmentB de Saint-Vis, J Vincent, S Vandenabeele, et al.
Oncoimmunology|May 4, 2016
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assayE Verronèse, A Delgado, J Valladeau-Guilemond, et al.
ESMO Open|June 5, 2025
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trialL Collet, J-C Noël, X Catteau, et al.
The Journal of Biological Chemistry|June 20, 1998
Leukocystatin, a new Class II cystatin expressed selectively by hematopoietic cellsS Halfon, J Ford, J Foster, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasisB Homey, M C Dieu-Nosjean, A Wiesenborn, et al.
Oncogenesis|July 26, 2016
TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expressionP Parroche, G Roblot, F Le Calvez-Kelm, et al.
Oncoimmunology|September 14, 2020
Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcomaA Dufresne, T Lesluyes, C Ménétrier-Caux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockadeJ-P Foy, C Bertolus, M-C Michallet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsO Trédan, C Ménétrier-Caux, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsO Trédan, C Ménétrier-Caux, I Ray-Coquard, et al.
Pageof 10